Table 3.
Demographic and clinical data of the patients before and after exenatide therapy according to BMI.
| Parameters | BMI < 40 kg/m2 (n:18) | BMI > 40 kg/m2(n:32) | ||||
|---|---|---|---|---|---|---|
| Baseline | 6. Month | p | Baseline | 6. Month | p | |
| HbA1c (%) | 8.9 ± 1.4 | 8.1 ± 1.5 | 0.047 | 9.3 ± 1.6 | 7.9 ± 1.8 | < 0.001 |
| AST (U/l) | 25.3 ± 14.2 | 19.9 ± 5.6 | 0.049 | 26.2 ± 16.3 | 22.1 ± 8.2 | 0.120 |
| ALT (U/l) | 30.1 ± 17 | 21.5 ± 8.1 | 0.004 | 29.5 ± 16.7 | 22 ± 10.1 | 0.005 |
| ALP (U/l) | 75.7 ± 27.6 | 78.2 ± 19.1 | 0.80 | 101.8 ± 33.9 | 87.6 ± 35.4 | 0.031 |
| GGT (U/l) | 30 (17–74) | 27 (18–61) | 0.399 | 34.5 (17–211) | 27 (13–144) | 0.005 |
| Creatine (mg/dl) | 0.89 ± 0.1 | 0.84 ± 0.1 | 0.008 | 0.83 ± 0.19 | 0.81 ± 0.18 | 0.46 |
| T.C(mg/dl) | 194.9 ± 40.7 | 188.9 ± 38.7 | 0.649 | 184.7 ± 35.3 | 176 ± 38.7 | 0.258 |
| LDL (mg/dl) | 133.4 ± 22.7 | 132.5 ± 38 | 0.878 | 124.5 ± 30.5 | 120.2 ± 29.7 | 0.243 |
| HDL (mg/dl) | 38.9 ± 8.1 | 40.5 ± 8.1 | 0.167 | 39.8 ± 8.1 | 39.9 ± 5.5 | 0.935 |
| Triglyceride (mg/dl) | 171 (98–1203) | 148 (74–607) | 0.255 | 177.5 (63–779) | 162 (63–665) | 0.063 |
| NFS | − 1.08 (− 2.08–1.61) | − 0.22 (− 2.33–0.65) | 0.214 | − 0.045 (− 1.23–4.17) | − 0.19 (− 1.55–1.79) | 0.004 |
| APRI | 0.25 ± 0.17 | 0.2 ± 0.08 | 0.071 | 0.22 ± 0.13 | 0.19 ± 0.11 | 0.217 |
BMI Body mass indeks, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma glutamyltransferase; T.C total cholesterol, HDL High-density lipoprotein, LDL low-density lipoprotein cholesterol, NFS NAFLD fibrosizscore, APRI AST to Platelet Ratio Index.